Gainers

• CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.
• Jin Medical International (NASDAQ:ZJYL) stock rose 20.43% to $2.24. The company's market cap stands at $14.5 million.
• EUDA Health Holdings (NASDAQ:EUDA) shares rose 13.25% to $17.55. The market value of their outstanding shares is at $46.4 million.
• Profound Medical (NASDAQ:PROF) shares increased by 11.6% to $6.54. The company's market cap stands at $214.1 million.
• Regeneron Pharmaceuticals (NASDAQ:REGN) shares increased by 11.14% to $910.0. The company's market cap stands at $84.2 billion. As per the news, the Q3 earnings report came out today.
• BeyondSpring (NASDAQ:BYSI) stock rose 10.31% to $0.57. The market value of their outstanding shares is at $21.2 million.

Losers

• Acumen Pharmaceuticals (NASDAQ:ABOS) shares fell 88.9% to $0.25 during Friday's regular session. The company's market cap stands at $165.6 million. The company's, Q3 earnings came out 4 days ago.
• ProMIS Neurosciences (NASDAQ:PMN) shares decreased by 64.08% to $3.98. The company's market cap stands at $99.3 million.
• Pelthos Therapeutics (AMEX:PTHS) stock declined by 40.45% to $9.85. The company's market cap stands at $63.3 million.
• Alphatec Holdings (NASDAQ:ATEC) stock decreased by 38.53% to $6.99. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q3 earnings report came out yesterday.
• Azora Therapeutics (NASDAQ:AZR) shares declined by 34.43% to $3.2. The market value of their outstanding shares is at $12.8 million.
• Pomdoctor (NASDAQ:POM) stock decreased by 31.66% to $1.36. The company's market cap stands at $5.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.